Specifications TableSubjectPsychiatry and Mental HealthSpecific subject areaSupplementary content to a focused review and meta-analysis of ^1^H-MRS studies on cerebral glutamate and GABA levels in high-risk of psychosis statesType of dataTable\
Figure\
Diagram\
PlotHow data were acquiredElectronic searches in Medline and Embase for case-control studies without restrictions on language, year, or publication status.\
Search terms: (Ultra high risk or Genetic high risk or Clinical high risk or High risk) and (Glutamate\* or GABA\* or Neurotransmitter\*) and (MRS or Spectroscopy or MR\* or Magnetic resonance spectroscopy or ^1^H-MRS)).\
The Cochrane Collaboration Review Manager software package (RevMan Version 5.3) was used to perform meta-analyses.Data formatRaw\
Analyzed\
FilteredParameters for data collectionA systematic review of all case-control studies that examined glutamate and/or GABA levels---measured with ^1^H-MRS---in individuals in high-risk states of psychosis states compared to healthy controls.Description of data collectionThe PRISMA group guidelines were followed. Searches were performed in Medline and Embase, and [clinicaltrials.gov](http://clinicaltrials.gov){#intref0015} was searched for ongoing or unpublished studies. Risk of bias was assessed with the Newcastle-Ottawa scale for case-control studies.\
Two researchers performed the literature search (CW and FZ).Data source locationInstitution: Copenhagen Research Center for Mental Health, CORE, Mental Health Center Copenhagen, Copenhagen University Hospital\
City/Town/Region: Hellerup\
Country: Denmark\
Latitude and longitude (and GPS coordinates) for collected samples/data: 55.738580; 12.548360 (55°44′20.7″N 12°32′39.2″E)Data accessibilityWith the articleRelated research articleChristina Wenneberg, Cerebral glutamate and GABA levels in high-risk of psychosis states: a focused review and meta-analysis of ^1^H-MRS studies, Schizophrenia Research Journal, Under review**Value of the Data**•The provided data are useful for gaining insight into the data underlying the review and meta-analysis. The supplementary data are useful for supporting points made in the main article.•Researchers showing further interest in the available literature on glutamatergic and GABAergic disturbances in high-risk for psychosis states, as well as those who read the article and wish to gain further insight into the underlying analyses, will benefit from the [raw data and supplementary material](#appsec1){ref-type="sec"}.•Researchers wishing to perform additional analyses based on the available data, e.g., different subgroups will be able to extract and apply data to further research.

1. Data description {#sec1}
===================

File I includes comprehensive meta-analyses for glutamate, Glx, and GABA as well as subgroup analyses according to the type of study (e.g., clinical or genetic high-risk; study performed on antipsychotic naïve participants or not).

[Fig. 1](#fig1){ref-type="fig"} depicts the PRISMA flow diagram of the included studies.Fig. 1PRISMA flow diagram of literature search and study selection.Fig. 1

[Table 1](#tbl1){ref-type="table"} lists the studies included in the review as well as all available measures and methodological variables.Table 1List of studies included in the review, available measures and methodological variables.Table 1Study and YearHigh-risk groupRegionVoxel size (cm)MetaboliteField strength (T)Acquisition sequenceEcho time (ms)Correction methodMean (SD) in articleBlock 2000GHRLeft frontal lobe4.0 × 3.0 × 2.5Glx1.5PRESS30Cr scalingYesBasal ganglia3.5 × 3.5 × 2.0Bloemen 2011UHRLeft hippocampus2 × 2 × 2Glu3PRESS36Not statedYesByun 2009UHR with MDDACC2 × 2 × 2Glx1.5PRESS40CSFYesUHR without MDDLeft DLPFCLeft thalamusCapizzano 2011GHR (1rst degree relative)ACC8 cm^3^Glx3PRESS30Cr scalingYesGHR (2nd degree relative)Left hippocampus4.5 cm^3^Da Silva 2018CHRMPFC2 × 4 × 3GABA3MEGA-PRESS68Not statedProvided by authorde la Fuente-Sandoval 2011UHRDorsal caudate2 × 2 × 2Glu, Glx3PRESS35CSFYesCerebellumde la Fuente-Sandoval 2015UHRMPFC3.0 × 2.5 × 2.5Glx, GABA3MEGA-PRESS68CSFYesDorsal caudate4.5 × 2.5 × 2.0Egerton 2014UHRLeft thalamus1.5 × 2.0 × 2.0Glu, Glx3PRESS30CSFYesACC2 × 2 × 2Grent-\'t-Jong 2018CHRRight MOG2 × 2 × 2GABA, Glx3MEGA-PRESS68Cr scalingRaw data availableKeshavan 2009GHRCaudate4.5cm^3^Glx1.5PRESS30CSFEstimatedLiemburg 2016UHRLeft LPFC2 × 2 × 2Glx1.5PRESS144CSFEstimatedLutkenhoff 2007GHRmesPFC2 × 2 × 2Glu3PRESS30CSFYesL-PFWM2 × 2 × 2Left hippocampus1.5 × 1.5 × 1.5Marenco 2016GHRACC2 × 2 × 4.5GABA3MEGA-PRESS68CSFProvided by authorMenschikov 2016UHR-SACC3 × 3 × 3GABA, Glx3MEGA-PRESS68Cr scalingProvided by authorModinos 2018UHRMPFC4.0 × 3.5 × 2.0GABA, Glu. Glx3MEGA-PRESS68Cr scalingCorrected values provided by authorNatsubori 2013UHRMPFC2 × 2 × 2Glx3STEAM15CSFYesNenadic 2015UHRRight hippocampus3 × 1 × 1Glu3PRESS30CSFYesLeft hippocampusPurdon 2007GHRMFC2.5 × 2.5 × 2.5Glu, Glx3STEAM20Cr scalingYesShakory 2018CHRLeft hippocampus3.0 × 1.4 × 1.0Glu, Glx3PRESS35CSFEstimated3.0 × 1.4 × 1.0Shendyapina 2015CHRDLPC?Glx3PRESS35Not statedNot givenLeft thalamusRight thalamusStone 2009ARMSACC2 × 2 × 2Glu, Gln, Glx3PRESS30CSFYesLeft hippocampus2.0 × 2.0 × 1.5Left thalamus1.5 × 2.0 × 2.0Tandon 2013GHRThalamus1.5 × 1.5 × 2.0Glx1.5PRESS30CSFYesCaudate1.5 × 1.5 × 2.0ACC1.5 × 1.5 × 2.0Thakkar 2017GHROccipital cortex4.0 × 2.4 × 2.5GABA, Glu, Gln, Glx7MEGA-sLASER36Cr scalingYesRight striatum4.0 × 2.4 × 2.5Left striatum4.0 × 2.4 × 2.5Tibbo 2004GHRRight MFC2.5cm^3^Glx3STEAM20Cr scalingYesValli 2011ARMSMedial temporal cortex2.0 × 2.0 × 1.5Glu3PRESS30CSFYesACC2 × 2 × 2Thalamus1.5 × 2.0 × 2.0Wang 2016UHRMPFC3 × 3 × 3GABA, Glx3MEGA-PRESS68CSFEstimatedWood 2010UHR-PTemporal lobe?Glx3PRESS30Not statedYesUHR-NPYoo 2009HGR (two relatives w. scz.)ACC2 × 2 × 2Glx1.5PRESS140CSFYesDLPC2.0 × 1.5 × 2.0Thalamus1.5 × 2.0 × 2.0[^1]

[Fig. 2](#fig2){ref-type="fig"} shows the meta-analysis and forest plot of all glutamate and Glx studies included in the review combined (including Glx measures for studies not reporting glutamate).Fig. 2Meta-analysis of all glutamate and Glx studies included in the meta-analysis combined (including Glx measures for studies not reporting glutamate). Forest plot showing standardized mean differences for ^1^H-MRS glutamate studies in high-risk versus controls. Error bars represent 95% confidence intervals. Abbreviations: ^1^H-MRS, proton magnetic resonance spectroscopy.Fig. 2

[Fig. 3](#fig3){ref-type="fig"} depicts the funnel plot of comparisons for studies included in the review for glutamate, Glx, and GABA, respectively, to assess signs of asymmetry reflecting possible publication bias.Fig. 3Funnel plot of comparison for studies included in the review. Top row left to right: Glutamate, Glx. Bottom row: GABA. Abbreviations: Glx, combined measures of glutamate and glutamine; GABA, gamma aminobutyric acid.Fig. 3

File II includes raw data of glutamate, Glx, and GABA levels for all included studies as well as author information and a range of demographical and clinical data extracted from the studies.

2. Experimental design, materials, and methods {#sec2}
==============================================

The associated review and meta-analysis \[[@bib1]\] was designed to establish whether there is any difference in baseline glutamate or GABA levels in individuals at high risk of developing psychosis (clinical or genetic high-risk states) compared to healthy controls as measured with ^1^H-MRS (levels of cerebral glutamate (glutamate, glutamine, or Glx) and/or GABA measured by applying a voxel of interest in a cerebral region) where HR and healthy controls are being compared.

High-risk states included clinical high risk as measured by clinical assessment tools (e.g., CAARMS, SIPS, or SOPS) as well as genetic high risk (having a relative with a psychotic disorder).

Embase and MEDLINE databases were searched for all relevant case/control studies without restrictions on language, year, or publication status. Studies fulfilling the search strategy were included search terms: (Ultra high risk or Genetic high risk or Clinical high risk or High risk) and (Glutamate\* or GABA\* or Neurotransmitter\*) and (MRS or Spectroscopy or MR\* or Magnetic resonance spectroscopy or ^1^H-MRS). If more than one scan was done in the same population, we only included the baseline values.

Reference lists of included studies and reviews were searched manually for additional studies, and [clinicaltrials.gov](http://clinicaltrials.gov){#intref0020} were searched for ongoing or unpublished studies, and the responsible researchers were contacted and asked to share potential unpublished data. We received no unpublished data.

We excluded studies with no comparison group or with the wrong comparison group (e.g., not healthy controls such as patients with schizophrenia or first-episode psychosis) as well as studies with previously published results.

The first search was performed on March 10th, 2019, and the final search was performed on April 9th, 2019, where no new eligible studies were found.

Two researchers performed the literature search (CW and FZ). Titles and abstracts screening, as well as full-text screening, were done independently by the two above mentioned researches. Any disagreements between the two independent assessors were resolved through discussion, with CW having the final word. Data from each study were independently extracted from the included studies by CW and FZ. CW compared the extracted data and determined the consensus. We used [covidence.org](http://covidence.org){#intref0025} for importing studies, title and abstracts screening, full-text screening, and for extracting and storing the data. Primary data extracted were available metabolite levels of GABA, Glx, glutamate, or glutamine measured by ^1^H-MRS. Risk of bias assessment of included studies was performed using the Newcastle-Ottawa scale.

Data were subsequently exported to The Cochrane Collaboration Review Manager software package (RevMan Version 5.3) were meta-analyses were performed using a random-effects, inverse-weighted variance model to calculate the pooled effect size since studies were expected to display high heterogeneity based on different correction methods, varying regions of interest, and diverse high-risk groups. The study effect size was weighted according to sample size. Heterogeneity was measured using the I^2^ value, with higher percentages signifying higher variation across studies in the meta-analysis. Significance was assessed using two-sided 95% confidence intervals.

Meta-analyses were performed separately for mean values of GABA, glutamate, and Glx (only two studies reported glutamine levels; hence, no meta-analysis was performed for this metabolite). If means or standard deviations were not published or only reported in figures, authors were contacted for this information. If we did not receive a response, means and SDs were estimated from represented figures using WebPlotDigitizer or---if not shown in figures---not included in the meta-analysis ([Table 1](#tbl1){ref-type="table"} provides more detail on this). Potential publication bias was assessed by visual inspection of funnel plots for studies on glutamate, Glx, and GABA, respectively ([Fig. 3](#fig3){ref-type="fig"}).

Each metabolite results was sorted into relevant subdomains of the brain ((1)frontal lobe, voxels placed in the anterior cingulate cortex (ACC), the medial prefrontal cortex (MPFC), or the dorsolateral prefrontal cortex (DLPFC); (2)the occipital lobe; (3)the temporal lobe; (4)hippocampus; (5)striatum, including basal ganglia and caudate; (6)thalamus; (7)cerebellum; and (8)white matter). Measures were not available for all regions for all metabolites. Each study was only represented once in each subdomain. For studies reporting subgroups of high-risk states with a shared control group, measures were treated as separate data sets, and the number of healthy controls was divided by the number of subgroups (always two). In studies where bilateral measures were provided, measures from the left side were included in the analyses.

When the number of studies allowed (more than two studies available), subgroup analyses were performed based on high-risk status, treatment with antipsychotic medication, and location of the voxel of interest in the frontal lobe.
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Appendix A. Supplementary data {#appsec1}
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The following are the Supplementary data to this article:Multimedia component 1Multimedia component 1Multimedia component 2Multimedia component 2

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.dib.2019.104920>.

[^1]: Abbreviations: T, Tesla; GHR, genetic high risk; UHR, ultra-high risk; MDD, major depressive disorder; CHR, clinical high risk; ARMS, at-risk mental state; UHR-P, UHR with transition; UHR-NP, UHR without transition; HGR, high genetic risk; scz., schizophrenia; ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; MPFC, medial prefrontal cortex; MOG, middle occipital gyrus; LPFC, lateral prefrontal cortex; MPFC, medial prefrontal cortex; PFWM, prefrontal white matter; Glx, combined measures of glutamate and glutamine; Glu, glutamate; GABA, gamma aminobutyric acid; PRESS, Point resolved spectroscopy; MEGA-PRESS, Meshcher--Garwood point resolved spectroscopy; STEAM, stimulated echo acquisition mode; Cr, creatine; CSF, cerebrospinal fluid.
